Art

J-GLOBAL ID：200902092687748658   Reference number：90A0362474

Phase II clinical trial on gene recombinant human interleukin 2 (γIL-2:TGP-3) on skin malignant cancers.

皮膚悪性腫ように対する遺伝子組換え型ヒトインターロイキン2(rIL-2:TGP-3)の臨床第2相試験

Author (2)： IKEDA SHIGEO (埼玉医大) ,  ISHIHARA KAZUYUKI (国立がんセ)
Material： Skin Cancer
Volume： 4  Issue： 2  Page： 367-387  Publication year： Dec. 1989 
JST Material Number： L0490A  ISSN： 0915-3535  Document type： Proceedings
Article type： 原著論文  Country of issue： Japan (JPN)  Language： JAPANESE (JA)

Thesaurus term： human ,...
Semi thesaurus term： immunoassay ,...

   To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=90A0362474&from=J-GLOBAL&jstjournalNo=L0490A") }}

JST classification (2)： Skin tumors(=neoplasms)  (GF04000X) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C)

Reference (39)：

• 1. Morgan, D.A., Ruscetti, F.W., Gallo, R.C. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193: 1007-1008, 1976.
• 2. Grimm, E.A., Mazumder, A., Zhang, H.G., Lymphokine-activated killer cell phenomenon: Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes. J. Exp. Med. 155: 1823-1841, 1982.
• 3. Grimm, E.A., Ramsey, K.M., Mazumder, A., Lymphokine-activated killer cell phenomenon II: Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. J. Exp. Med. 157: 884-897, 1983.
• 4. Chang, A.E., Hyatt, C.L., Rosenberg, S.A. Systemic administration of recombinant human interleukin-2 in mice. J. Biol. Response Modif.3: 561-572, 1984.
• 5. Henney, C.S., Kuribayashi, K., Kern, D.E., Interleukin-2 augments natural killer activity. Nature 291: 333-337, 1981.

Terms in the title (7)： 皮膚悪性腫よう ,  遺伝子組換え ,  ヒト ,  インターロイキン2 ,  TGP-3 ,  臨床 ,  第2相試験